DelNova is developing proprietary therapies by leveraging advances in drug delivery technology. They have identified an anticholinesterase class of drugs as a means of accelerating muscle recovery by indirectly increasing the neurotransmitter deficit caused by botulinum toxin.

Staffing & Recruiting

Health Care

Biotechnology

Delivery

Delnova

Mary Gardner

Hannah Roddy

Dimas Jiménez

Steven Yoelin

Sameer B. Shah

The Leadership Team at DelNova, comprising the CEO and Founder, Chief Scientist, and Chief Medical Strategist, oversees the strategic direction, scientific research, and clinical development of proprietary therapies leveraging advanced drug delivery technologies, specifically targeting muscle recovery post-botulinum toxin.

Leadership Team

Scientific Team

Leadership Team

About

Team members

Other teams at Delnova

Scientific Team